AbbVie Inc. $ABBV Stock Sold by Fulcrum Wealth Advisors LLC

Fulcrum Wealth Advisors LLC decreased its stake in AbbVie Inc. (NYSE:ABBV) by 47.5% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,021 shares of the company’s stock after selling 1,831 shares during the period. Fulcrum Wealth Advisors LLC’s holdings in AbbVie were worth $529,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Kintegral Advisory LLC raised its stake in AbbVie by 0.6% during the 3rd quarter. Kintegral Advisory LLC now owns 52,691 shares of the company’s stock worth $13,783,000 after acquiring an additional 297 shares in the last quarter. New England Research & Management Inc. lifted its position in AbbVie by 3.1% in the third quarter. New England Research & Management Inc. now owns 25,544 shares of the company’s stock valued at $6,682,000 after acquiring an additional 770 shares during the last quarter. Intergy Private Wealth LLC lifted its position in AbbVie by 11.0% in the third quarter. Intergy Private Wealth LLC now owns 956 shares of the company’s stock valued at $250,000 after acquiring an additional 95 shares during the last quarter. Avail Investment Partners LLC lifted its position in AbbVie by 6.1% in the third quarter. Avail Investment Partners LLC now owns 2,391 shares of the company’s stock valued at $625,000 after acquiring an additional 138 shares during the last quarter. Finally, RKL Wealth Management LLC boosted its stake in AbbVie by 8.0% in the third quarter. RKL Wealth Management LLC now owns 18,566 shares of the company’s stock valued at $4,857,000 after acquiring an additional 1,375 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ABBV shares. Citigroup raised their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. BMO Capital Markets lifted their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Barclays boosted their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Leerink Partners upped their target price on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Finally, Piper Sandler upped their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $277.18.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
• Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
• Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

AbbVie Price Performance

Shares of AbbVie stock opened at $285.32 on Friday. The firm’s fifty day simple moving average is $262.74 and its 200-day simple moving average is $239.22. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $291.40. The stock has a market capitalization of $504.10 billion, a price-to-earnings ratio of 80.60, a PEG ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.